# Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant

> **NCT03301168** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Bellicum Pharmaceuticals** · enrollment: 120 (estimated)

## Conditions studied

- Acute Lymphoblastic Leukemia
- Leukemia, Acute Myeloid (AML), Child
- Lymphoma, Non-Hodgkin
- Myelodysplastic Syndromes
- Primary Immune Deficiency Disorder
- Osteopetrosis
- Cytopenia
- Hemoglobinopathy in Children
- Anemia, Aplastic

## Interventions

- **BIOLOGICAL:** BPX-501 T cells
- **DRUG:** Rimiducid

## Key facts

- **NCT ID:** NCT03301168
- **Lead sponsor:** Bellicum Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2014-04
- **Primary completion:** 2021-05-11
- **Final completion:** 2034-05
- **Target enrollment:** 120 (ESTIMATED)
- **Last updated:** 2022-07-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03301168

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03301168, "Study of Gene Modified Donor T-cells Following TCR Alpha Beta Positive Depleted Stem Cell Transplant". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT03301168. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*